In a study conducted by the University of Cincinnati College of Medicine, scientists analyzed 22 pancreatic tumor samples from patients across the United States to investigate how tumor characteristics differ by racial background. The research, published in Cancer Research, identified notable variations that may help explain why pancreatic cancer affects patients differently.
Key findings on tumor cell composition
The team discovered that tumors from Black patients contained fewer of the most common pancreatic cancer cells and a higher proportion of cells displaying mixed characteristics. Some of these mixed‑type cells have previously been linked to drug resistance, although the study did not determine whether they directly influence treatment outcomes.
Immune‑cell differences observed
In addition to cellular differences, the researchers found that tumors from Black patients had a greater presence of B cells—a type of immune cell—and larger clusters of immune cells overall. Early evidence suggests that certain B cells might suppress the body’s anti‑cancer response, but the clinical significance of this observation remains unclear.
Genetic drivers appear consistent
Despite the cellular and immune variations, the study reported no significant differences between the groups in the major genetic mutations known to drive pancreatic cancer. This suggests that while the genetic blueprint of the disease may be similar, the way tumors behave and interact with the immune system can differ.
Implications for health disparities
Pancreatic cancer is about 20% more likely to develop in Black Americans than in non‑African American populations, according to the investigators. Lead author Nina Steele, Ph.D., emphasized that overlooking diverse ancestry in medical research creates blind spots that hinder the search for effective cures. “Ignoring diverse ancestry leaves blind spots in the search for a cure,” she told Fox News Digital.
Expert commentary
Dr. Raymond Wadlow, a gastrointestinal medical oncologist at Inova Schar Cancer Institute in Virginia, noted that pancreatic cancer has historically been difficult to treat with immunotherapy because the tumor often subverts the immune system. “The pancreatic tumor subverts the immune system so that it is fighting for it instead of for the host,” he explained. Wadlow stressed that while the new findings are intriguing, they are still far from changing everyday patient care.
Calls for broader inclusion in trials
Both Steele and Wadlow stressed the importance of enrolling patients from diverse backgrounds in clinical trials. Steele said, “Clinical trials must reflect the entire population at risk in order to find treatments that can help all patients, not just some.” The researchers also noted the need for studies that include pancreatic tissue from individuals without cancer to better understand when these differences arise.
Next steps
The study’s authors acknowledge several limitations. They have not yet established how the intermediate tumor cells affect survival or whether they respond differently to standard chemotherapy. Larger, more diverse studies are required to determine if the observed differences translate into distinct treatment outcomes or survival rates.
Wadlow encouraged newly diagnosed patients to discuss hereditary genetic testing with their doctors, as identifying inherited mutations can guide testing for family members. “If we find an inherited mutation, then family members can be tested,” he said.
The research was funded in part by the National Cancer Institute, underscoring federal support for investigations that aim to reduce health disparities and improve outcomes for all pancreatic cancer patients.
Original reporting: Fox News (HLL/CB) — read the source article.